Global Chemotherapy Induced Neutropenia Drug Market Insights, Research Forecast to 2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 129

Report ID: 5428

The global Chemotherapy Induced Neutropenia Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Chemotherapy Induced Neutropenia Drug market based on company, product type, end user and key regions.

This report studies the global market size of Chemotherapy Induced Neutropenia Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Chemotherapy Induced Neutropenia Drug in these regions.
This research report categorizes the global Chemotherapy Induced Neutropenia Drug market by top players/brands, region, type and end user. This report also studies the global Chemotherapy Induced Neutropenia Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
BeyondSpring Pharmaceuticals Inc
Biocon Ltd
Bolder Biotechnology Inc
Cellerant Therapeutics Inc
Chong Kun Dang Pharmaceutical Corp
Cinfa Biotech SL
Dr. Reddy's Laboratories Ltd
Gene Techno Science Co Ltd
Generon (Shanghai) Corp Ltd
Genexine Inc
GlycoMimetics Inc
Hanmi Pharmaceuticals Co Ltd
Intas Pharmaceuticals Ltd
Lupin Ltd
Mycenax Biotech Inc
Myelo Therapeutics GmbH
Nohla Therapeutics Inc
Octapharma AG
Pangen Biotech Inc.
Pfenex Inc

Market size by Product
F-627
BBT-018
Filgrastim
GW-003
NLA-101
Others
Market size by End User
Hospital
Clinic
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Chemotherapy Induced Neutropenia Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Chemotherapy Induced Neutropenia Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Chemotherapy Induced Neutropenia Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Chemotherapy Induced Neutropenia Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Chemotherapy Induced Neutropenia Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Chemotherapy Induced Neutropenia Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Study Coverage
1.1 Chemotherapy Induced Neutropenia Drug Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Chemotherapy Induced Neutropenia Drug Market Size Growth Rate by Product
1.4.2 F-627
1.4.3 BBT-018
1.4.4 Filgrastim
1.4.5 GW-003
1.4.6 NLA-101
1.4.7 Others
1.5 Market by End User
1.5.1 Global Chemotherapy Induced Neutropenia Drug Market Size Growth Rate by End User
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Chemotherapy Induced Neutropenia Drug Market Size
2.1.1 Global Chemotherapy Induced Neutropenia Drug Revenue 2014-2025
2.1.2 Global Chemotherapy Induced Neutropenia Drug Sales 2014-2025
2.2 Chemotherapy Induced Neutropenia Drug Growth Rate by Regions
2.2.1 Global Chemotherapy Induced Neutropenia Drug Sales by Regions
2.2.2 Global Chemotherapy Induced Neutropenia Drug Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Chemotherapy Induced Neutropenia Drug Sales by Manufacturers
3.1.1 Chemotherapy Induced Neutropenia Drug Sales by Manufacturers
3.1.2 Chemotherapy Induced Neutropenia Drug Sales Market Share by Manufacturers
3.1.3 Global Chemotherapy Induced Neutropenia Drug Market Concentration Ratio (CR5 and HHI)
3.2 Chemotherapy Induced Neutropenia Drug Revenue by Manufacturers
3.2.1 Chemotherapy Induced Neutropenia Drug Revenue by Manufacturers (2014-2019)
3.2.2 Chemotherapy Induced Neutropenia Drug Revenue Share by Manufacturers (2014-2019)
3.3 Chemotherapy Induced Neutropenia Drug Price by Manufacturers
3.4 Chemotherapy Induced Neutropenia Drug Manufacturing Base Distribution, Product Types
3.4.1 Chemotherapy Induced Neutropenia Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Chemotherapy Induced Neutropenia Drug Product Type
3.4.3 Date of International Manufacturers Enter into Chemotherapy Induced Neutropenia Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Chemotherapy Induced Neutropenia Drug Sales by Product
4.2 Global Chemotherapy Induced Neutropenia Drug Revenue by Product
4.3 Chemotherapy Induced Neutropenia Drug Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Chemotherapy Induced Neutropenia Drug Breakdown Data by End User

6 North America
6.1 North America Chemotherapy Induced Neutropenia Drug by Countries
6.1.1 North America Chemotherapy Induced Neutropenia Drug Sales by Countries
6.1.2 North America Chemotherapy Induced Neutropenia Drug Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Chemotherapy Induced Neutropenia Drug by Product
6.3 North America Chemotherapy Induced Neutropenia Drug by End User

7 Europe
7.1 Europe Chemotherapy Induced Neutropenia Drug by Countries
7.1.1 Europe Chemotherapy Induced Neutropenia Drug Sales by Countries
7.1.2 Europe Chemotherapy Induced Neutropenia Drug Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Chemotherapy Induced Neutropenia Drug by Product
7.3 Europe Chemotherapy Induced Neutropenia Drug by End User

8 Asia Pacific
8.1 Asia Pacific Chemotherapy Induced Neutropenia Drug by Countries
8.1.1 Asia Pacific Chemotherapy Induced Neutropenia Drug Sales by Countries
8.1.2 Asia Pacific Chemotherapy Induced Neutropenia Drug Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Chemotherapy Induced Neutropenia Drug by Product
8.3 Asia Pacific Chemotherapy Induced Neutropenia Drug by End User

9 Central & South America
9.1 Central & South America Chemotherapy Induced Neutropenia Drug by Countries
9.1.1 Central & South America Chemotherapy Induced Neutropenia Drug Sales by Countries
9.1.2 Central & South America Chemotherapy Induced Neutropenia Drug Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Chemotherapy Induced Neutropenia Drug by Product
9.3 Central & South America Chemotherapy Induced Neutropenia Drug by End User

10 Middle East and Africa
10.1 Middle East and Africa Chemotherapy Induced Neutropenia Drug by Countries
10.1.1 Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Countries
10.1.2 Middle East and Africa Chemotherapy Induced Neutropenia Drug Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Chemotherapy Induced Neutropenia Drug by Product
10.3 Middle East and Africa Chemotherapy Induced Neutropenia Drug by End User

11 Company Profiles
11.1 BeyondSpring Pharmaceuticals Inc
11.1.1 BeyondSpring Pharmaceuticals Inc Company Details
11.1.2 Company Business Overview
11.1.3 BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2014-2019)
11.1.4 BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Products Offered
11.1.5 BeyondSpring Pharmaceuticals Inc Recent Development
11.2 Biocon Ltd
11.2.1 Biocon Ltd Company Details
11.2.2 Company Business Overview
11.2.3 Biocon Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Biocon Ltd Chemotherapy Induced Neutropenia Drug Products Offered
11.2.5 Biocon Ltd Recent Development
11.3 Bolder Biotechnology Inc
11.3.1 Bolder Biotechnology Inc Company Details
11.3.2 Company Business Overview
11.3.3 Bolder Biotechnology Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Bolder Biotechnology Inc Chemotherapy Induced Neutropenia Drug Products Offered
11.3.5 Bolder Biotechnology Inc Recent Development
11.4 Cellerant Therapeutics Inc
11.4.1 Cellerant Therapeutics Inc Company Details
11.4.2 Company Business Overview
11.4.3 Cellerant Therapeutics Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Cellerant Therapeutics Inc Chemotherapy Induced Neutropenia Drug Products Offered
11.4.5 Cellerant Therapeutics Inc Recent Development
11.5 Chong Kun Dang Pharmaceutical Corp
11.5.1 Chong Kun Dang Pharmaceutical Corp Company Details
11.5.2 Company Business Overview
11.5.3 Chong Kun Dang Pharmaceutical Corp Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Chong Kun Dang Pharmaceutical Corp Chemotherapy Induced Neutropenia Drug Products Offered
11.5.5 Chong Kun Dang Pharmaceutical Corp Recent Development
11.6 Cinfa Biotech SL
11.6.1 Cinfa Biotech SL Company Details
11.6.2 Company Business Overview
11.6.3 Cinfa Biotech SL Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Cinfa Biotech SL Chemotherapy Induced Neutropenia Drug Products Offered
11.6.5 Cinfa Biotech SL Recent Development
11.7 Dr. Reddy's Laboratories Ltd
11.7.1 Dr. Reddy's Laboratories Ltd Company Details
11.7.2 Company Business Overview
11.7.3 Dr. Reddy's Laboratories Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Dr. Reddy's Laboratories Ltd Chemotherapy Induced Neutropenia Drug Products Offered
11.7.5 Dr. Reddy's Laboratories Ltd Recent Development
11.8 Gene Techno Science Co Ltd
11.8.1 Gene Techno Science Co Ltd Company Details
11.8.2 Company Business Overview
11.8.3 Gene Techno Science Co Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Gene Techno Science Co Ltd Chemotherapy Induced Neutropenia Drug Products Offered
11.8.5 Gene Techno Science Co Ltd Recent Development
11.9 Generon (Shanghai) Corp Ltd
11.9.1 Generon (Shanghai) Corp Ltd Company Details
11.9.2 Company Business Overview
11.9.3 Generon (Shanghai) Corp Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2014-2019)
11.9.4 Generon (Shanghai) Corp Ltd Chemotherapy Induced Neutropenia Drug Products Offered
11.9.5 Generon (Shanghai) Corp Ltd Recent Development
11.10 Genexine Inc
11.10.1 Genexine Inc Company Details
11.10.2 Company Business Overview
11.10.3 Genexine Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Genexine Inc Chemotherapy Induced Neutropenia Drug Products Offered
11.10.5 Genexine Inc Recent Development
11.11 GlycoMimetics Inc
11.12 Hanmi Pharmaceuticals Co Ltd
11.13 Intas Pharmaceuticals Ltd
11.14 Lupin Ltd
11.15 Mycenax Biotech Inc
11.16 Myelo Therapeutics GmbH
11.17 Nohla Therapeutics Inc
11.18 Octapharma AG
11.19 Pangen Biotech Inc.
11.20 Pfenex Inc

12 Future Forecast
12.1 Chemotherapy Induced Neutropenia Drug Market Forecast by Regions
12.1.1 Global Chemotherapy Induced Neutropenia Drug Sales Forecast by Regions 2019-2025
12.1.2 Global Chemotherapy Induced Neutropenia Drug Revenue Forecast by Regions 2019-2025
12.2 Chemotherapy Induced Neutropenia Drug Market Forecast by Product
12.2.1 Global Chemotherapy Induced Neutropenia Drug Sales Forecast by Product 2019-2025
12.2.2 Global Chemotherapy Induced Neutropenia Drug Revenue Forecast by Product 2019-2025
12.3 Chemotherapy Induced Neutropenia Drug Market Forecast by End User
12.4 North America Chemotherapy Induced Neutropenia Drug Forecast
12.5 Europe Chemotherapy Induced Neutropenia Drug Forecast
12.6 Asia Pacific Chemotherapy Induced Neutropenia Drug Forecast
12.7 Central & South America Chemotherapy Induced Neutropenia Drug Forecast
12.8 Middle East and Africa Chemotherapy Induced Neutropenia Drug Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Chemotherapy Induced Neutropenia Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer